Business
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. (Paris time) / 9:30 a.m. (New York time). Trading of the ordinary shares of
About this update from Nanobiotix Sa
[{"type":"image","alt":"Nanobiotix S.A.","displaySize":"","headline":null,"caption":"Nanobiotix S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/eJ7NkIHzztwPinGRQcbZqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998","width":300,"height":100},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/eJ7NkIHzztwPinGRQcbZqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MA--/https://media.zenfs.com/en/globenewswire.com/ae5026f0933e6f98c5e60a809a606998","width":300,"height":100}},"lazy":false},{"type":"text","content":"PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announces today the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m. (Paris time) / 9:30 a.m. (New York time).","length":470,"tagName":"p"},{"type":"text","content":"Trading of the ordinary shares of the Company was halted at the request of the Company on May 21, 2026 from 9:00 a.m. CEST in the context of the previously announced offering consisting of (i) a public offering of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) and (ii) an offering of (a) its Ordinary Shares and (b) pre-funded warrants to subscribe for Ordinary Shares, exclusively addressed to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended, and certain other countries (excluding the United States and Canada) (the “International Offering” and, together with the U.S. Offering, the “Global Offering”), in order to allow for the confirmation of allocations to investors and the announcement of the pricing of the Global Offering.","length":964,"tagName":"p"},{"type":"text","content":"About NANOBIOTIX","length":16,"tagName":"p"},{"type":"text","content":"Nanobiotix is ...